sftd
Anti-TNFá Monoclonal Antibody, Infliximab: Reduced Exacerbations in Symptomatic Moderate Asthma
Filed in archive Studies , Treatment by Gloria Gamat on October 11, 2006
Anti-TNFá Monoclonal Antibody, Infliximab: Reduced Exacerbations in Symptomatic Moderate Asthma
In the first October 2006 issue of the American Journal of Respiratory and Critical Care Medicine (published by the American Thoracic Society), a reseach paper reported that treatment of anti-tumor necrosis factor alpha, an anti-inflammatory monoclonal antibody to patients with symptomatic moderate asthma resulted to fewer disease exacerbations compared to the placebo group.

Trevor T. Hansel, M.D., Ph.D., of the National Heart and Lung Institute at Royal Brompton Hospital in London with 11 other associates infused 14 patients with infliximab, a monoclonal antibody that binds and neutralizes tumor necrosis factor alpha (TNFá).

Infliximab popular brand name is Remicade(R).

According to Dr. Hansel:

"Anti-TNFá therapy has been shown to be effective in patients with rheumatoid arthritis, Ankylosing spondylitis, Crohn's disease and psoriasis, but ineffective in patients with chronic obstructive pulmonary disease (COPD).

Preliminary reports of efficacy in asthma patients with concomitant rheumatoid arthritis have been encouraging. Small prospective studies of a soluble receptor directed against TNFá in severe refractory asthma have also shown improvements in lung function and airway hyperresponsiveness."

"Treatment with infliximab reduced the number of moderate exacerbations in patients with asthma, as monitored by morning and evening use of an electronic spirometer incorporating a clinical diary. Although infliximab therapy did not show significant efficacy for the primary endpoint of monitoring peak expiratory flow (PEF), it did produce a significant decrease in the diurnal (during the day) variation in the PEF rate."


No adverse events associated with using the monoclonal antibody for treatment were reported, meriting anti-TNFá therapy further study in larger clinical trials in severe asthma patients.

Read more at Science Daily.

Photo Credit: [asthma.upmc.com]

Permalink: Anti-TNFá Monoclonal Antibody, Infliximab: Reduced Exacerbations in Symptomatic Moderate Asthma
Tags: antitumor  necrosis  factor  alpha  TNFa  infliximab  remicade  asthma  anti  monoclonal+antibody 
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/38948
img Addthis img Ask img Blinklist img del.icio.us img Digg img Fark img Facebook img Google img Lycos img Ma.gnolia Add this page to Mister Wong Mr Wong img Netscape img Netvousz img Newsvine img Reddit img StumbleUpon img Slashdot img Tailrank img Technorati img Wink img Yahoo

Vote for Anti-TNFá Monoclonal Antibody, Infliximab: Reduced Exacerbations in Symptomatic Moderate Asthma:

  • Currently 7.50/10
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
Rating: 7.50 out of 4 vote(s) cast.
 
Subscribe
Share It
Popular posts from our other blogs:
RSSrss
See all blog subscribe options
Google google
What is RSS?
Yahoo! yahoo
Addthis Subscribe using any feed reader!
Bloglines Bloglines
Newsletter

TwitterFollow us on Twitter!